Novo shares rise as HIMS halt sales of some obesity drugs

Go back to Novo shares rise as HIMS halt sales of some obesity drugs

Hims and Hers (HIMS) PT Raised to $39 at Truist Securities

February 26, 2025 5:30 AM EST

Truist Securities analyst Jailendra Singh raised the price target on Hims and Hers (NYSE: HIMS) to $39.00 (from $24.00) while maintaining a Hold rating.

The analyst comments "We had a post-quarterly call with HIMS to discuss 4Q24 results, puts and takes in weight loss solution outlook,... More